Table 1.

Patients investigated

PatientDiagnosisTreatment at time of analysis
A1 Ki-1 lymphoma Cyclophosphamide, dexamethasone  
A2 Ewing sarcoma Vincristine, Adriamycin, ifosfamide  
A3 Ewing sarcoma Vincristine, Adriamycin, ifosfamide  
A4 Peripheral neuroectodermal tumor Vincristine, actinomycin D, ifosfamide 
A5 Peripheral neuroectodermal tumor Vincristine, actinomycin D, ifosfamide  
A6 Hodgkin disease OEPA: vincristine, Adriamycin, etoposide, prednisolone  
A7 Ewing sarcoma EVAIA: vincristine, doxorubicin, etoposide, ifosfamide  
A8 Germ cell tumor Etoposide, cisplatin, ifosfamide 
A9 Neuroblastoma Vindesine, cisplatin, etoposide 
A10 Hodgkin disease OEPA: vincristine, Adriamycin, etoposide, prednisolone  
B1 Osteosarcoma Doxorubicin 
B2 Osteosarcoma Doxorubicin  
B3 Non-Hodgkin lymphoma Cyclophosphamide, dexamethasone 
B4 Osteosarcoma High-dose methotrexate 
B5 Amegakaryocytosis Busulfan, cyclophosphamide 
B6 Nephroblastoma Actinomycin D, vincristine 
PatientDiagnosisTreatment at time of analysis
A1 Ki-1 lymphoma Cyclophosphamide, dexamethasone  
A2 Ewing sarcoma Vincristine, Adriamycin, ifosfamide  
A3 Ewing sarcoma Vincristine, Adriamycin, ifosfamide  
A4 Peripheral neuroectodermal tumor Vincristine, actinomycin D, ifosfamide 
A5 Peripheral neuroectodermal tumor Vincristine, actinomycin D, ifosfamide  
A6 Hodgkin disease OEPA: vincristine, Adriamycin, etoposide, prednisolone  
A7 Ewing sarcoma EVAIA: vincristine, doxorubicin, etoposide, ifosfamide  
A8 Germ cell tumor Etoposide, cisplatin, ifosfamide 
A9 Neuroblastoma Vindesine, cisplatin, etoposide 
A10 Hodgkin disease OEPA: vincristine, Adriamycin, etoposide, prednisolone  
B1 Osteosarcoma Doxorubicin 
B2 Osteosarcoma Doxorubicin  
B3 Non-Hodgkin lymphoma Cyclophosphamide, dexamethasone 
B4 Osteosarcoma High-dose methotrexate 
B5 Amegakaryocytosis Busulfan, cyclophosphamide 
B6 Nephroblastoma Actinomycin D, vincristine 
Close Modal

or Create an Account

Close Modal
Close Modal